Skip to main content
. 2016 Jan 6;2:15023. doi: 10.1038/npjbcancer.2015.23

Figure 2.

Figure 2

Forest plot displaying hazard ratios (HR) and 95% confidence intervals (CI) for RFS with DD therapy in patient subgroups from C9741 defined by tumor characteristics (number of positive nodes and tumor size), PAM50 assay (intrinsic subtype, proliferation score, and ROR-PT score), and immunohistochemistry (ER/HER2, Ki67, CK5/6, and EGFR). CK, cytokeratin; DD, dose dense; EGFR, epidermal growth factor receptor; ER, estrogen receptor; IHC, immunohistochemistry; N, number of subjects; RFS, recurrence-free survival; ROR-PT, risk of recurrence score.